An Adherence Tool to Manage Narcotic -Addicted HIV Patients

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Healthy Adults
Interventions
DRUG

Naltrexone and 2-butanol

50mg of Naltrexone and 40 or 80 mg of 2-butanol (depending on Stability Formulation in the first part of the study)

DRUG

2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)

a capsule-in-capsule (CIC) design, will be prepared in the pharmacy by incorporating 40 or 80 mg (determined from the first part of the study) of 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form) in a size 0 double blind hard gel capsule.

Trial Locations (1)

32611

University of Florida, Gainesville

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Xhale Assurance

INDUSTRY

NCT02194764 - An Adherence Tool to Manage Narcotic -Addicted HIV Patients | Biotech Hunter | Biotech Hunter